Ipsen, Sky­hawk ink deal worth up to $1.8B; He­p­i­on to wind down NASH tri­al

Plus, news about Aslan, Take­da, Astel­las, Sum­it­o­mo Mit­sui, Kynos Ther­a­peu­tics, Oculis and Vaxxin­i­ty:

Ipsen, Sky­hawk Ther­a­peu­tics pen neu­ro­log­i­cal deal: Ipsen

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER